Crohn's disease future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m Bot: Removing from Primary care |
||
| Line 7: | Line 7: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
[[Category:Needs content]] | [[Category:Needs content]] | ||
| Line 17: | Line 19: | ||
[[Category:Conditions diagnosed by stool test]] | [[Category:Conditions diagnosed by stool test]] | ||
[[Category:Abdominal pain]] | [[Category:Abdominal pain]] | ||
Latest revision as of 21:10, 29 July 2020
|
Crohn's disease |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Crohn's disease future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Crohn's disease future or investigational therapies |
|
Crohn's disease future or investigational therapies in the news |
|
Blogs on Crohn's disease future or investigational therapies |
|
Risk calculators and risk factors for Crohn's disease future or investigational therapies |
Ustekinumab
Recent studies have found that in patients refarctory to treatment with tumor necrosis factor (TNF) antagonists, subcutaneously administered maintenance doses of ustekinumab showed a significant benefit in terms of clinical response but not remission, and were efficacious during a period of 22 weeks.[1]